Novo extends Caisson deal
13.03.2014 - Denmark's Novo Nordisk and Texan biotech Caisson have expanded the scope of their insulin delivery partnership.
The new license agreement gives Novo Nordisk the exclusive rights to commercialise insulin conjugated to Caisson's heparosan polymers. The Danish pharma company also gains the non-exclusive rights to leverage this platform technology for drug delivery across other core therapeutic areas, including other diabetes care products, human growth hormone therapy, treatments for obesity and for inflammatory diseases, such as Crohn’s, lupus, rheumatoid and psoriatic arthritis. In a 2012 deal worth more than US$100m, Novo Nordisk had licensed Caisson's technology, which uses a naturally occurring polymer found in the body. The platform enables delivery of drugs in ‘stealth mode’ making the process more patient-friendly.
For the use of its technology, Caisson, a wholly owned subsidiary of Heparinex, L.L.C, will receive up to US$167m (€120m) in milestone payments, plus potential long-term residual royalties. "Novo Nordisk has completed feasibility studies that pre-clinically validate Caisson’s heparosan-based drug delivery technology for product pharmacokinetics and enhanced half-life," said Paul DeAngelis, Chief Scientist of the US firm. Caisson CEO Thomas Harlan added: "As a respected healthcare leader, Novo Nordisk has been an ideal partner and provides the infrastructure and expertise necessary to develop these much-needed therapeutic products."